Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
天然产物
/
细胞周期
细胞骨架 自噬 夹竹桃科 结构分类
/
微管
自噬 生物碱 长春花属
/ Vinorelbine ditartrate

酒石酸长春瑞滨 /Vinorelbine ditartrate {[allProObj[0].p_purity_real_show]}

货号：A676353 同义名： 酒石酸长春瑞宾 / Nor-5'-anhydrovinblastine ditartrate;KW-2307

Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Vinorelbine ditartrate 化学结构 CAS号：125317-39-7
Vinorelbine ditartrate 化学结构
CAS号：125317-39-7
Vinorelbine ditartrate 3D分子结构
CAS号：125317-39-7
Vinorelbine ditartrate 化学结构 CAS号：125317-39-7
Vinorelbine ditartrate 3D分子结构 CAS号：125317-39-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Vinorelbine ditartrate 纯度/质量文件 产品仅供科研

货号：A676353 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 Autophagy ↓ 其他靶点 纯度
SBI-0206965 +++

ULK2, IC50: 711 nM

ULK1, IC50: 108 nM

 		97%
Hydroxychloroquine sulfate ✔ 99%
Valproic acid sodium ✔ HDAC 97%
PFK-015 ++

PFKFB3, IC50: 207 nM

 		99%+
MRT68921 hydrochloride ++++

ULK2, IC50: 1.1 nM

ULK1, IC50: 2.9 nM

 		99%+
ROC-325 ✔ 99%+
Autophinib +++

Autophagy, IC50: 40 nM

 		97%
Lys05 ✔ 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Vinorelbine ditartrate 生物活性

描述 Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin and always been used as an anti-mitotic chemotherapy drug. Vinorelbine Tartrate exhibits > 20 fold selectivity over axonal microtubules and inhibit proliferation of multiple human tumor cell lines (IC50 = 1.25 nM in HeLa cells). When blocks metaphase or anaphase transition by suppression of microtubule dynamics, the IC50 value is 3.8 nM. Vinorelbine is involved in underlying processes in human tumors, reversing multi-drug resistance reversal of human lung cancer A549/DDP cells, drug sensitivity to cisplatin and intracellular accumulation of rhodamine-123 was increased while expression of P-glycoprotein (P-gp), multi-drug resistance-associated protein (MRP1) and glutathione-S-transferase II (GST-II) in A549/DDP cells was decreased[4]. When treated with breast cancer, Vinorelbine alone was equivalent to fluoropyrimidine treatment in RR (p = 0.79) while vinorelbine group gave similar results as other regimens for OS (p = 0.849) and PFS (p = 0.143). The RR of vinorelbine-combined regimens was slightly better than that of the other regimens (OR, 1.17), but the difference was not statistically significant. In neoadjuvant setting, vinorelbine treatment was as active as AC (doxorubicin, cyclophosphamide) or DAC (doxorubicin, cyclophosphamide, docetaxel) regimens with respect to RR (p = 0.76) and pathologic complete response (pCR; p = 0.77), but showed lower occurrence of grade 3/4 adverse effects[5]. In A phase I/II trial neratinib (240 mg) plus vinorelbine (25 mg/m2) was established as the MTD in phase I (n=12). While In phase II, 79 patients with HER2-positive metastatic breast cancer were treated at the MTD. The most common treatment-related adverse events were diarrhea (96%), neutropenia (54%), and nausea (50%). Three patients discontinued treatment due to diarrhea. No clinically important skin side-effects were observed. The OR rate in assessable phase II patients was 41% (no prior lapatinib) and 8% (prior lapatinib)[6].
作用机制 Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals[3].

Vinorelbine ditartrate 动物研究

Dose Mice: 1.2 mg/kg[3] (i.v.) Rat: 0.12 mg/kg - 1.2 mg/kg[3] (i.v.)
Administration i.v.

Vinorelbine ditartrate 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02645175 Metastatic Breast Cancer ... 展开 >> Fatigue 收起 << Phase 2 Terminated(Business Decision) December 2018 -
NCT00055887 Lung Cancer Phase 3 Withdrawn(Study never started.... 展开 >> No patients were enrolled.) 收起 << - United States, Arizona ... 展开 >> St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States, 85013 United States, Idaho North Idaho Cancer Center Coeur d'Alene, Idaho, United States, 83814 United States, Kentucky Cancer Center at Lexington Clinic Lexington, Kentucky, United States, 40504 United States, Louisiana Willis - Knighton Cancer Center Shreveport, Louisiana, United States, 71103-3951 United States, Maryland St. Agnes Cancer Center Baltimore, Maryland, United States, 21229 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 United States, Washington Providence Everett Medical Center - Pacific Campus Everett, Washington, United States, 98206 United States, West Virginia Schiffler Cancer Center Wheeling, West Virginia, United States, 26003 Belgium Algemeen Ziekenhuis Middelheim Antwerp, Belgium, 2020 Canada, Alberta Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, Ontario Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 1C4 Canada, Quebec CHUS-Hopital Fleurimont Fleurimont, Quebec, Canada, J1H 5N4 Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 Hopital Notre- Dame du CHUM Montreal, Quebec, Canada, H2L 4M1 McGill University Montreal, Quebec, Canada, H2W 1S6 Centre Hospitalier Universitaire de Quebec Quebec City, Quebec, Canada, G1R 2J6 Israel Soroka University Medical Center Beer-Sheva, Israel, 84101 Rambam Medical Center Haifa, Israel, 31096 Sheba Medical Center Tel Hashomer, Israel, 52621 Tel-Aviv Sourasky Medical Center Tel-Aviv, Israel, 64239 收起 <<
NCT00002823 Lung Cancer Phase 3 Completed - -

Vinorelbine ditartrate 参考文献

[1]16(2 Suppl 4):9-14.

[2]Nowak RP. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat Chem Biol. 2018 Jul;14(7):706-714. doi: 10.1038/s41589-018-0055-y. Epub 2018 Jun 11.

[3]Fellous A. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol. 1989 Apr;16(2 Suppl 4):9-14.

[4] Awada A. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013 Jan;24(1):109-16. doi: 10.1093/annonc/mds284. Epub 2012 Sep 11.

Vinorelbine ditartrate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.93mL

0.19mL

0.09mL

4.63mL

0.93mL

0.46mL

9.27mL

1.85mL

0.93mL

Vinorelbine ditartrate 技术信息

CAS号125317-39-7
分子式C53H66N4O20
分子量 1079.106
别名 酒石酸长春瑞宾 ;Nor-5'-anhydrovinblastine ditartrate;KW-2307;Vinorelbine (tartrate);KW-2307 ditartrate
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,2-8°C
溶解度

DMSO: 120 mg/mL(111.2 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(92.67 mM)，配合低频超声助溶
动物实验配方

Tags: Vinorelbine ditartrate | 125317-39-7 | KW-2307 | Nor-5'-anhydrovinblastine ditartrate | KW2307 | KW 2307 | Cell Cycle/DNA Damage | Cytoskeleton | Autophagy | Microtubule/Tubulin | Autophagy | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Vinorelbine ditartrate 纯度/质量文件 | Vinorelbine ditartrate 亚型比较 | Vinorelbine ditartrate 生物活性 | Vinorelbine ditartrate 动物研究 | Vinorelbine ditartrate 临床数据 | Vinorelbine ditartrate 参考文献 | Vinorelbine ditartrate 实验方案 | Vinorelbine ditartrate 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z